[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-with-rapid-ventricular-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-with-rapid-ventricular-response":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100647156","phase-4-comparing-two-heart-medicines-for-fast-irregular-heartbeat-atrial-fibrillation-100647156",false,"NCT07706075","Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)","Verapamil Versus Metoprolol for Rate Control in Hemodynamically Stable Atrial Fibrillation With Rapid Ventricular Response","Inclusion Criteria:\n\n* Adult patients aged 18 years and above presenting to the Emergency Department\n* Confirmed diagnosis of atrial fibrillation with rapid ventricular response (heart rate ≥110 bpm) on 12-lead ECG\n* Hemodynamically stable at the time of enrollment (systolic blood pressure ≥90 mmHg, no shock, no acute pulmonary edema)\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability, cardiogenic shock, or acute decompensated heart failure\n* Known pre-excitation syndrome (e.g., Wolff-Parkinson-White syndrome) on baseline ECG\n* Severe left ventricular systolic dysfunction (ejection fraction less than 30%) as determined by echocardiography\n* Known hypersensitivity or contraindication to verapamil or metoprolol\n* Patients already taking rate control agents (beta-blockers, calcium channel blockers, or digoxin) in the last 24 hours\n* Major bradycardia (heart rate less than 50 bpm) or AV block (second or third degree) on baseline ECG\n* Active bronchospasm or severe obstruction of pulmonary disease\n* Severe hepatic impairment (Child-Pugh Class C) or acute renal failure (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy or breastfeeding\n* Inability to give informed consent","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to learn whether intravenous verapamil or intravenous metoprolol controls heart rate more effectively in adult patients who arrive at the emergency department with atrial fibrillation and a fast heart rate (rapid ventricular response), but who are otherwise medically stable. Atrial fibrillation with a rapid heart rate is a common emergency, and doctors currently choose between these two standard medicines based on personal preference rather than strong local evidence, since there is limited research on this comparison in Pakistani patients.\n\nThe main questions this study aims to answer are:\n\nDoes a higher proportion of patients reach a target heart rate of less than 110 beats per minute within 30 minutes with verapamil compared to metoprolol? Which medicine controls the heart rate faster, on average? Are there differences in side effects (such as low blood pressure, slow heart rate, or breathing problems) between the two medicines? Researchers will compare a group of patients receiving verapamil to a group receiving metoprolol to see if one medicine controls the heart rate faster and more safely than the other.\n\nParticipants will:\n\n1. Receive either verapamil or metoprolol through an IV, with the dose given according to standard protocols\n2. Have their heart rate, blood pressure, and oxygen levels monitored continuously for 30 minutes after the medicine is given\n3. Be observed for any side effects during this monitoring period Both medicines used in this study are already standard, guideline-recommended treatments for this condition, so participation will not change or delay the medical care patients would normally receive.",[26,27],"Atrial Fibrillation (AF)","Atrial Fibrillation With Rapid Ventricular Response",[29,30,31,32,33,34,35,36,37],"atrial fibrillation","Rapid ventricular Response","Rate Control","Verapamil","Metoprolol","Calcium Channel Blockers","Beta Blockers","Cardiac Arrythmia","Hemodynamically unstable","NOT_YET_RECRUITING","2026-07-30",{"date":41,"type":42},"2026-08-03","ACTUAL",{"date":44,"type":20},"2027-01-01",{"date":46,"type":20},"2027-08-01",{"name":48,"class":49},"Muhammad Ali Javed","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100648534","clinical-validation-of-smd-rvecg-for-predicting-atrial-fibrillation-with-rapid-ventricular-response-within-2-hours-100648534","NCT07722039","Clinical Validation of SMD-RVECG for Predicting Atrial Fibrillation With Rapid Ventricular Response Within 2 Hours","A Retrospective, Single Center, Single Arm, Superiority Confirmatory Study to Evaluate the Clinical Validity of SMD-RVECG, Artificial Intelligence Software to Predict the Risk of Developing Atrial Fibrillation With Rapid Ventricular Response (AF With RVR) Within 2 Hours Using Single Lead-Based Electrocardiogram Analysis","AFRVR","Inclusion Criteria:\n\n* Continuous single-lead electrocardiogram data collected through VitalDB at Seoul National University Hospital between September 1, 2022, and September 30, 2025\n* Participant aged 19 years or older at the time of electrocardiogram data collection\n* Electrocardiogram data meeting either of the following group definitions:\n\n  * AF with RVR-positive group: atrial fibrillation followed by rapid ventricular response, defined as an average heart rate of 110 beats per minute or greater for at least 30 seconds, with available electrocardiogram data for up to 2 hours before the onset of rapid ventricular response and after the onset in accordance with the protocol\n  * AF with RVR-negative group: atrial fibrillation without rapid ventricular response, with 3 hours of electrocardiogram data available before a selected index time corresponding to a similar time during hospitalization as that used for positive cases\n* If the relevant episode occurred within 2 hours after the start of electrocardiogram recording, availability of electrocardiogram data from the start of recording through up to 1 hour after the episode, with a minimum electrocardiogram recording duration of 10 minutes\n* Other data considered suitable for the study by the principal investigator\n\nExclusion Criteria:\n\n* Electrocardiogram data considered to be of inadequate quality because of noise, poor equipment handling, unclear signals, artifacts, or similar problems\n* Electrocardiogram data with signal loss of 5 percent or greater\n* Electrocardiogram data with a heart rate below 30 beats per minute or above 300 beats per minute\n* Data collected from a participant who was pregnant or breastfeeding at the time of data collection\n* Data previously used for training or validation of the artificial intelligence model\n* Electrocardiogram data from a participant whose baseline heart rate remained at 110 beats per minute or greater irrespective of atrial fibrillation\n* Data considered unsuitable for this clinical study by the principal investigator","19 Years",{"count":60,"type":20},348,"OBSERVATIONAL","The purpose of this retrospective study is to evaluate the clinical performance of SMD-RVECG, an artificial intelligence-based medical device software that analyzes single-lead electrocardiogram data to predict the risk of atrial fibrillation with rapid ventricular response occurring within 2 hours.\n\nA total of 348 eligible electrocardiogram datasets collected through VitalDB at Seoul National University Hospital will be included. Atrial fibrillation with rapid ventricular response is defined in this study as atrial fibrillation accompanied by an average heart rate of 110 beats per minute or greater for at least 30 seconds.\n\nEligible datasets will be classified as positive or negative for atrial fibrillation with rapid ventricular response. Two qualified physicians blinded to the software results will review the electrocardiogram data and relevant medical records to establish the reference-standard classification. The blinded electrocardiogram datasets will then be analyzed using SMD-RVECG, and the software-generated predictions will be compared with the reference standard to evaluate clinical performance.",[26,27],[27,65,66,67,68,69,70,71],"AF With RVR","Rapid Ventricular Response","Atrial Fibrillation Prediction","Single-Lead Electrocardiogram","Artificial Intelligence","Software as a Medical Device","SMD-RVECG","2026-07-20",{"date":74,"type":42},"2026-07-23",{"date":76,"type":20},"2026-10-01",{"date":78,"type":20},"2026-12-31",{"name":80,"class":81},"HUINNO Co., Ltd","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100537307","phase-3-oral-bisoprolol-vs-iv-diltiazem-in-atrial-fibrillation-or-flutter-with-rapid-ventricular-rate-100537307","NCT06276127","Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.","Oral Bisoprolol Versus Intravenous Diltiazem in the Management of Atrial Fibrillation or Flutter With Rapid Ventricular Rate in the Emergency Department: A Randomized Controlled Trial","BisoAF","Inclusion Criteria:\n\n* ≥ 18 years old.\n* Atrial fibrillation (RVR) or Atrial flutter on electrocardiogram.\n* Heart rate \\>120 beats\u002Fmin\n* Stable patient with stable vital signs (Defined as having a SBP \\>110 mmHg, oxygen saturation \\> 94% on room air or with a simple face mask, a respiratory rate within normal limits, being conscious and oriented, and not having any concurrent life-threatening conditions such as myocardial infarction (MI) or Class IV heart failure).\n* Mentally competent patient who can understand and sign the consent form.\n\nExclusion Criteria:\n\n* Acute myocardial infarction.\n* Known congenital and acquired valvular defects.\n* Pre-excitation syndromes.\n* Ventricular rate \\> 220beats\u002Fmin.\n* Administration of AV nodal blocking agents within the previous 24 h (beta blockers, non-dihydropyridine calcium channel blockers, digoxin and amiodarone or receiving regular maintains oral dose).\n* Allergy to either bisoprolol or diltiazem.\n* Severe hepatic and renal failure.\n* Pregnancy \u002F breastfeeding.\n* A history of cocaine or methamphetamine use within 24 hours before arrival.\n* Known Asthmatic.",true,{"count":92,"type":20},60,[94],"PHASE3","INTRODUCTION: The study focuses on comparing the effectiveness of oral Bisoprolol, a beta-1 adrenergic receptor blocker, against intravenous Diltiazem, a calcium channel blocker, in treating rapid atrial fibrillation or flutter with rapid ventricular response in an emergency setting. This research aims to fill the gap in empirical evidence regarding the use of oral Bisoprolol for these conditions, potentially offering a convenient, evidence-based alternative for patient management in emergency departments where established protocols are lacking.\n\nMETHOD: This study is a randomized controlled trial targeting patients who present to the emergency room with symptomatic atrial fibrillation or flutter and rapid ventricular response requiring intervention. Participants will be split into two groups and undergo continuous monitoring of vital signs and regular electrocardiograms to ensure safety and document any adverse effects. The primary focus is on patient safety while evaluating the efficacy of the treatments.\n\nAIM: Evaluate the efficacy and safety of oral bisoprolol in treating atrial fibrillation or atrial flutter with rapid ventricular response in an emergency department setting.\n\nPRIMARY OJECTIVES: The primary efficacy outcome will be evaluated by achieving a HR\\\u003C110 beats per minute or a decrease ≥20% of baseline HR at 60 minutes. The primary safety outcome measures are HR \\\u003C 60 bpm and SBP \\\u003C 95 mm Hg.\n\nSECONDARY OBJECTIVES: The use of Rescue medication, proportion of patients who required hospitalization, worsening of heart failure or pulmonary oedema, side effect of medication ( dizziness, headaches, gastrointestinal symptoms)\n\nPATEINT POPULATION: Adults (18 and older) presenting to the emergency department at Sultan Qaboos University Hospital with symptomatic atrial fibrillation or atrial flutter with rapid ventricular response requiring treatment.\n\nINTERVENTION: A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg) or a single intravenous dose of Diltiazem at 0.25 mg\u002Fkg (to a maximum dose of 30 mg).\n\nCLINICAL MEASURMENT: Heart rate recorded every 15 minutes up to the 90-minute mark, with a 12-lead ECG performed every 30 minutes.\n\nOUTCOME: For therapy to be considered effective, patients must achieve a ventricular rate ≤110\u002Fmin or experience a drop-in ventricular rate of at least 20% at 60 minutes.",[27,97],"Atrial Flutter With Rapid Ventricular Response",[99,100,101,102],"Bisoprolol","AF","Diltiazem","Atrial flutter","2025-03-11",{"date":105,"type":42},"2025-03-14",{"date":107,"type":20},"2025-04",{"date":109,"type":20},"2027-06",{"name":111,"class":112},"Oman Medical Speciality Board","OTHER_GOV",1]